14.04.2011 • News

Sanofi Weighing Options For U.S. Dermatology Unit

Sanofi-Aventis said it was considering "strategic alternatives" for its U.S. dermatology business, as it seeks to refocus its business on growth areas such as diabetes and cancer treatments.

The company's comment came after Bloomberg News published a story on Wednesday on how Sanofi was seeking to sell the unit, which the report said could be valued around €300 million.

Sanofi has said previously that its dermatology business could come under review because it was too small. It does not disclose sales for the unit.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.